Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanism and clinical trial evidence without systematic search methodology.
PubMed 28137217 · doi:10.2174/1381612823666170130155036
What was done
This narrative review summarizes the biological mechanism and clinical trial evidence for the fully human anti-PCSK9 monoclonal antibodies alirocumab and evolocumab. It assesses their efficacy across various clinical populations, including patients with statin intolerance, those receiving add-on therapy or monotherapy, and individuals with familial hypercholesterolemia.
What was found
Inhibition of PCSK9 with alirocumab or evolocumab lowers LDL-C by approximately 50% to 70% across diverse patient populations. Target LDL-C goal achievement rates range from 87% to 98% in treated individuals depending on baseline risk. Preliminary data noted an approximately 50% improvement in cardiovascular morbidity and mortality, with definitive large-scale cardiovascular endpoint trials pending at the time of publication.
Why it matters
PCSK9 inhibitors provide a potent therapeutic option for substantial LDL-C lowering in patients who cannot tolerate statins or who fail to achieve risk-stratified lipid targets on standard therapy.
Limits
The abstract describes a narrative review rather than a systematic review or meta-analysis. Precise sample sizes, specific trial-level data, adverse effect profiles, and finalized cardiovascular outcome results are not reported in the abstract.
Cited by
- supports PCSK9 inhibitors were first approved in 2015.